Literature DB >> 8535257

Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.

M B Kroeger Smith1, C A Rouzer, L A Taneyhill, N A Smith, S H Hughes, P L Boyer, P A Janssen, H Moereels, L Koymans, E Arnold.   

Abstract

Computer modeling studies have been carried out on three nonnucleoside inhibitors complexed with human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), using crystal coordinate data from a subset of the protein surrounding the binding pocket region. Results from the minimizations of solvated complexes of 2-cyclopropyl-4-methyl-5,11-dihydro-5H-dipyrido[3,2-b :2',3'-e][1,4] diazepin-6-one (nevirapine), alpha-anilino-2, 6-dibromophenylacetamide (alpha-APA), and 8-chloro-tetrahydro-imidazo(4,5,1-jk)(1,4)-benzodiazepin-2(1H)-thi one (TIBO) show that all three inhibitors maintain a very similar conformational shape, roughly overlay each other in the binding pocket, and appear to function as pi-electron donors to aromatic side-chain residues surrounding the pocket. However, side-chain residues adapt to each bound inhibitor in a highly specific manner, closing down around the surface of the drug to make tight van der Waals contacts. Consequently, the results from the calculated minimizations reveal that only when the inhibitors are modeled in a site constructed from coordinate data obtained from their particular RT complex can the calculated binding energies be relied upon to predict the correct orientation of the drug in the pocket. In the correct site, these binding energies correlate with EC50 values determined for all three inhibitors in our laboratory. Analysis of the components of the binding energy reveals that, for all three inhibitors, solvation of the drug is endothermic, but solvation of the protein is exothermic, and the sum favors complex formation. In general, the protein is energetically more stable and the drug less stable in their complexes as compared to the reactant conformations. For all three inhibitors, interaction with the protein in the complex is highly favorable. Interactions of the inhibitors with individual residues correlate with crystallographic and site-specific mutational data. pi-Stacking interactions are important in binding and correlate with drug HOMO RHF/6-31G* energies. Modeling results are discussed with respect to the mechanism of complex formation and the design of nonnucleoside inhibitors that will be more effective against mutants of HIV-1 RT that are resistant to the currently available drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8535257      PMCID: PMC2142988          DOI: 10.1002/pro.5560041026

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  37 in total

Review 1.  Retroviral reverse transcriptase: synthesis, structure, and function.

Authors:  S P Goff
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

3.  The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.

Authors:  D W Rodgers; S J Gamblin; B A Harris; S Ray; J S Culp; B Hellmig; D J Woolf; C Debouck; S C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

4.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes.

Authors:  J Ren; R Esnouf; E Garman; D Somers; C Ross; I Kirby; J Keeling; G Darby; Y Jones; D Stuart
Journal:  Nat Struct Biol       Date:  1995-04

5.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.

Authors:  R Esnouf; J Ren; C Ross; Y Jones; D Stammers; D Stuart
Journal:  Nat Struct Biol       Date:  1995-04

Review 6.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization.

Authors:  S K Burley; G A Petsko
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

7.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

8.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

9.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.

Authors:  J Ding; K Das; C Tantillo; W Zhang; A D Clark; S Jessen; X Lu; Y Hsiou; A Jacobo-Molina; K Andries
Journal:  Structure       Date:  1995-04-15       Impact factor: 5.006

10.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

Authors:  R A Spence; W M Kati; K S Anderson; K A Johnson
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

View more
  6 in total

Review 1.  In search of a selective antiviral chemotherapy.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

2.  Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.

Authors:  Elena N Peletskaya; Alex A Kogon; Steven Tuske; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase.

Authors:  D V Nissley; P L Boyer; D J Garfinkel; S H Hughes; J N Strathern
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

4.  An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.

Authors:  Peter M-U Ung; James B Dunbar; Jason E Gestwicki; Heather A Carlson
Journal:  J Med Chem       Date:  2014-08-01       Impact factor: 7.446

5.  Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.

Authors:  Favourite N Cele; Muthusamy Ramesh; Mahmoud Es Soliman
Journal:  Drug Des Devel Ther       Date:  2016-04-11       Impact factor: 4.162

Review 6.  Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.

Authors:  Lucianna Helene Santos; Rafaela Salgado Ferreira; Ernesto Raúl Caffarena
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.